$1.61
-0.65-28.76%
Perspective Therapeutics (CATX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.27 | $-0.30 | $-0.35 | $-0.32 |
| Actual | $-0.22 | $-0.25 | $-0.51 | $-0.35 |
| Surprise | +18.5% | +16.7% | -45.7% | -9.38% |
| Revenue | ||||
| Estimate | $113960 | $179744 | $254188 | $244104 |
| Actual | $81000 | $76000 | $43000 | $209000 |
| Surprise | -28.9% | -57.7% | -83.1% | -14.4% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $-0.24 | $-0.26 | $-0.28 |
| Revenue | |||
| Consensus | $81432 | $84760 | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 10, 2026 | $-0.22 | $-0.27 | 18.5 % |
| Q1 | May 11, 2026 | $-0.25 | $-0.30 | 16.7 % |
| Q4 | Mar 16, 2026 | $-0.51 | $-0.35 | -45.7 % |
| Q3 | Nov 10, 2025 | $-0.35 | $-0.32 | -9.38 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 10, 2026 | $81.00K | $113.96K | -28.9 % |
| Q1 | May 11, 2026 | $76.00K | $179.74K | -57.7 % |
| Q4 | Mar 16, 2026 | $43.00K | $254.19K | -83.1 % |
| Q3 | Nov 10, 2025 | $209.00K | $244.10K | -14.4 % |